Fungus Found Evolving Resistance To Drug Meant For Humans, Pg11

Key Highlights:

• A study revealed that the fungus Pneumocystis jirovecii is developing resistance to the drug mycophenolic acid (MPA).
• MPA is an immunosuppressive drug prescribed to solid-organ transplant recipients to prevent organ rejection.
• The resistance stems from mutations in the fungal IMPDH enzyme, which is similar to the human enzyme targeted by MPA.
• Researchers analyzed 163 P. jirovecii samples from various countries, predominantly from transplant patients.

Detailed Insights:

• Pneumocystis jirovecii is known to cause severe lung infections, specifically Pneumocystis Pneumonia (PCP), in individuals with compromised immune systems.
• MPA, marketed under names like CellCept and Myfortic, works by inhibiting IMPDH in human immune cells to suppress the immune response.
• The observed fungal mutations allow P. jirovecii to tolerate MPA, providing a selective advantage for the fungus in patients taking the drug.
• This phenomenon represents an unexpected form of antimicrobial resistance, where a drug intended for human cells inadvertently pressures a pathogen.
• The findings suggest a need to re-evaluate current immunosuppressive strategies and infection control measures for transplant patients.
• The study underscores the broader potential for pathogens to evolve resistance to therapies not directly aimed at them.

Scientific/Technical Concepts Involved:

• Pneumocystis jirovecii: A specific fungus that causes a serious lung infection, particularly in immunocompromised individuals.
• Mycophenolic acid (MPA): An immunosuppressive drug used to prevent the rejection of transplanted organs by suppressing the immune system.
• IMPDH (Inosine monophosphate dehydrogenase): An enzyme crucial for the synthesis of purines, which is targeted by MPA in human cells and also present in the fungus.
• Antimicrobial resistance: The ability of microorganisms to grow or survive in the presence of a drug that would normally kill or inhibit them.